# Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

> **NCT04066088** · PHASE4 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **OTHER:** Placebo
- **DRUG:** Guanfacine extended release (GXR)

## Key facts

- **NCT ID:** NCT04066088
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-08-21
- **Final completion:** 2020-08-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI departure from institution
- **Last updated:** 2020-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04066088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04066088, "Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04066088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*